Uppsala, Sweden – July 3, 2025 – As previously communicated Orexo will announce the Interim Report for the second quarter of 2025 on July 16 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

To attend via teleconference where you can ask questions verbally use this link: https://events.inderes.com/orexo/q2-report-2025/dial-in
When registered you will be provided phone numbers and a conference ID to access the conference.

To attend via webcast:
https://orexo.events.inderes.com/q2-report-2025/register

Prior to the event the presentation material will be available on the website under Investors/Report Archive

For further information contact:
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.

For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

Läs mer på MFN